145 related articles for article (PubMed ID: 33506273)
21. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
22. Lapatinib side-effect management.
Frankel C; Palmieri FM
Clin J Oncol Nurs; 2010 Apr; 14(2):223-33. PubMed ID: 20350896
[TBL] [Abstract][Full Text] [Related]
23. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
[TBL] [Abstract][Full Text] [Related]
24. Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea.
Song YK; Oh JM
Support Care Cancer; 2020 Aug; 28(8):3711-3720. PubMed ID: 31820128
[TBL] [Abstract][Full Text] [Related]
25. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
26. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Ramos-Ruperez E; Escudero-Vilaplana V; Ruiz-Briones P; Collado-Borrell R; Villanueva-Bueno C; Revuelta-Herrero JL; González-Haba E; Garcia-Gonzalez X; Ibañez-Garcia S; Perez-Ramirez S; Zatarain-Nicolás E; Herranz A; Sanjurjo M
Front Oncol; 2023; 13():1220305. PubMed ID: 37692846
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
28. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
29. Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Leong C; Czaykowski P; Geirnaert M; Katz A; Dragan R; Yogendran M; Raymond C
Can J Public Health; 2021 Jun; 112(3):530-540. PubMed ID: 33471346
[TBL] [Abstract][Full Text] [Related]
30. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
31. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Collet JP; Montalescot G; Blanchet B; Tanguy ML; Golmard JL; Choussat R; Beygui F; Payot L; Vignolles N; Metzger JP; Thomas D
Circulation; 2004 Oct; 110(16):2361-7. PubMed ID: 15477397
[TBL] [Abstract][Full Text] [Related]
32. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy-induced diarrhea: A review of the literature.
Pessi MA; Zilembo N; Haspinger ER; Molino L; Di Cosimo S; Garassino M; Ripamonti CI
Crit Rev Oncol Hematol; 2014 May; 90(2):165-79. PubMed ID: 24373918
[TBL] [Abstract][Full Text] [Related]
34. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
35. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
36. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
37. Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Gonzalez-Anleo C; Martin-Conde M; Romero-Jimenez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
JMIR Mhealth Uhealth; 2020 Oct; 8(10):e20480. PubMed ID: 33064100
[TBL] [Abstract][Full Text] [Related]
38. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
40. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]